skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Resultados 1 2 3 4 5 next page
Refinado por: Nome da Publicação: Blood remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy
Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy

Sperr, Wolfgang R. ; Zach, Otto ; Poell, Iris ; Kundi, Michael ; Herndlhofer, Susanne ; Jaeger, Ulrich ; Knoebl, Paul ; Weltermann, Ansgar ; Valent, Peter

Blood, 2011-11, Vol.118 (21), p.2504-2504 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
2
Prognostic Factors Predicting Survival in De Novo AML Patients Requiring Intensive Care
Prognostic Factors Predicting Survival in De Novo AML Patients Requiring Intensive Care
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prognostic Factors Predicting Survival in De Novo AML Patients Requiring Intensive Care

Schellongowski, Peter ; Staudinger, Thomas ; Laczika, Klaus ; Locker, Gottfried ; Bojic, Andja ; Jaeger, Ulrich ; Valent, Peter ; Sperr, Wolfgang R.

Blood, 2007-11, Vol.110 (11), p.2860-2860 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
3
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Byrd, John C. ; Hillmen, Peter ; O'Brien, Susan ; Barrientos, Jacqueline C. ; Reddy, Nishitha M. ; Coutre, Steven ; Tam, Constantine S. ; Mulligan, Stephen P. ; Jaeger, Ulrich ; Barr, Paul M. ; Furman, Richard R. ; Kipps, Thomas J. ; Thornton, Patrick ; Moreno, Carol ; Montillo, Marco ; Pagel, John M. ; Burger, Jan A. ; Woyach, Jennifer A. ; Dai, Sandra ; Vezan, Remus ; James, Danelle F. ; Brown, Jennifer R.

Blood, 2019-05, Vol.133 (19), p.2031-2042 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
4
Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells
Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Awasthi, Rakesh ; Waldron, Edward ; Grupp, Stephan ; Pulsipher, Michael A. ; Bader, Peter ; Schuster, Stephen J ; Maziarz, Richard T ; Waller, Edmund K. ; Jaeger, Ulrich ; Thieblemont, Catherine ; Dreyling, Martin ; Fowler, Nathan ; Maier, Harald Jakob ; Willert, Jennifer

Blood, 2023-11, Vol.142 (Supplement 1), p.4872-4872 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion
Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion
Material Type:
Artigo 		Adicionar ao Meu Espaço

Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion

Siddiqi, Tanya ; Jaeger, Ulrich ; Moshkovich, Olga ; Braverman, Julia ; Liu, Fei Fei ; Lanar, Sally ; Miera, Matthew ; Shah, Selam ; Devlen, Jennifer ; Salles, Gilles

Blood, 2021-11, Vol.138 (Supplement 1), p.4098-4098 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
6
Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Seymour, John F. ; Kipps, Thomas J. ; Eichhorst, Barbara F. ; Hillmen, Peter ; D'Rozario, James ; Assouline, Sarit ; Owen, Carolyn ; Robak, Tadeusz ; de la Serna, Javier ; Jaeger, Ulrich ; Cartron, Guillaume ; Montillo, Marco ; Lamanna, Nicole ; Kim, Su Young ; Wu, Jenny ; Jiang, Yanwen ; Wang, Jue ; Lefebure, Marcus ; Boyer, Michelle ; Humphrey, Kathryn ; Kater, Arnon P

Blood, 2019-11, Vol.134 (Supplement_1), p.355-355 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
7
Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy
Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy

Siddiqi, Tanya ; Jaeger, Ulrich ; Moshkovich, Olga ; Devlen, Jennifer ; Miera, Matthew ; Williams, Agnes ; Hasskarl, Jens ; Liu, Fei Fei ; Braverman, Julia ; Salles, Gilles

Blood, 2020-11, Vol.136 (Supplement 1), p.22-23 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
8
Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial
Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial

Jaeger, Ulrich ; Bishop, Michael R. ; Salles, Gilles ; Schuster, Stephen J. ; Maziarz, Richard T. ; Han, Xia ; Savchenko, Alexander ; Roscoe, Nathan ; Orlando, Elena ; Knoblock, Dawson ; Tiwari, Ranjan ; Bubuteishvili Pacaud, Lida ; Corradini, Paolo

Blood, 2020-11, Vol.136 (Supplement 1), p.48-49 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
9
A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
Material Type:
Artigo 		Adicionar ao Meu Espaço

A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

Flinn, Ian W. ; Jaeger, Ulrich ; Shah, Nirav N. ; Blaise, Didier ; Briones, Javier ; Shune, Leyla ; Boissel, Nicolas ; Bondanza, Attilio ; Lu, Darlene ; Zhu, Xu ; Engels, Boris ; Brogdon, Jennifer L ; Mataraza, Jennifer ; Davis, Jaclyn ; Marchal, Anne Laure ; Mariconti, Luisa ; Moschetta, Michele ; Parseval, Laure Moutouh-de ; Barba, Pere ; Dickinson, Michael

Blood, 2021-11, Vol.138 (Supplement 1), p.740-740 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
10
Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)
Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Kater, Arnon P. ; Kipps, Thomas J. ; Eichhorst, Barbara ; Hillmen, Peter ; D'Rozario, James ; Owen, Carolyn ; Assouline, Sarit E ; Lamanna, Nicole ; Robak, Tadeusz J. ; de la Serna, Javier ; Jaeger, Ulrich ; Cartron, Guillaume ; Montillo, Marco ; Mellink, Clemens ; Chyla, Brenda J. ; Wilson, Cameron ; Wu, Jenny ; Jiang, Yanwen ; Lefebure, Marcus ; Boyer, Michelle ; Seymour, John F.

Blood, 2020-11, Vol.136 (Supplement 1), p.19-21 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.